Connor, Clark & Lunn Investment Management (CC&L)
ARQT icon

Connor, Clark & Lunn Investment Management (CC&L)’s Arcutis Biotherapeutics ARQT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-119,029
Closed -$1.31M – 1303
2023
Q1 		$1.31M Buy
119,029
+8,303
+7% +$120K 0.01% 650
2022
Q4 		$1.64M Buy
+110,726
New +$1.93M 0.01% 596

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ARQT Position: Q2 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Arcutis Biotherapeutics (ARQT) in Q2 2023, closing a stake of 119,029 shares — an estimated $1.31M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ARQT in Q4 2022 and held it in 2 quarters. The position peaked at $1.64M in Q4 2022. 136 funds tracked by Wall St. Rank hold ARQT as of Q2 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Arcutis Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 119,029 Arcutis Biotherapeutics shares in Q2 2023, an estimated $1.31M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Arcutis Biotherapeutics in Q4 2022 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Arcutis Biotherapeutics position peaked at $1.64M in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2023, filed 10 Aug 2023.